French biotech EG 427 has had success with its urinary incontinence DNA therapy, EG110A, showing a more than 80% reduction in ...

A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Preliminary results from a small trial offer the clearest evidence yet that the brain disease’s progression can be slowed.

AskBio Inc. (AskBio), a gene therapy company wholly owned and independently operated as a subsidiary of Bayer AG, will deliver 6 presentations offering insights into the research and development of ...

Treatment introduces an expansion of the scope of gene therapies that might lead to similar treatments for neurodegenerative ...

D Molecular Therapeutics (FDMT) offers attractive growth potential with strong cash reserves and promising late-stage gene ...

JCR will present non-clinical data from its novel JUST-AAV gene therapy platform technology in an oral session at the ESGCT ...

After three patients died, the maker of an investigational gene therapy stopped shipments of the drug after it refused to ...

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for ...

The AAV vector market is advancing due to the rising demand for gene therapies targeting disease causes at the cellular level ...

Breakthrough Therapy designation granted based on FDA’s review of available clinical evidence of safety and efficacy from all 12 patients treated in Part A of the REVEAL Phase 1/2 trials Finalized FDA ...